Latest Security News

Dexus Convenience Retail REIT reported solid half-year results for FY25, maintaining distribution guidance while enhancing portfolio quality through strategic divestments and commencing a major redevelopment at Glass House Mountains.

Keybridge Capital has been hit with an immediate $4.6 million loan repayment demand from Yowie Group, triggered by delays in its capital raising efforts obstructed by WAM Active Limited.

DEXUS Convenience Retail REIT has announced a final distribution of AUD 0.05138 per security for the quarter ending December 2024, confirming steady income for investors ahead of the February payment date.

Dexus Convenience Retail REIT has rebounded strongly with a $14.7 million net profit for the half-year ending December 2024, underpinned by a resilient portfolio and active redevelopment plans.

BlinkLab has secured North Shore Pediatric Therapy as the second US clinical site in its autism diagnostic study, enhancing recruitment and data quality with a leading Chicago-based specialist.

Golden Horse Minerals has reported compelling soil geochemistry results at its Southern Cross Project, revealing multiple significant gold anomalies and securing a strategic mining lease to bolster exploration efforts.

VIP Gloves Limited has obtained a short-term interest-free loan of approximately AUD$1 million ahead of a planned share placement, as it faces potential delisting from the ASX pending a critical reinstatement decision.

Trek Metals reports a significant high-grade manganese discovery at the Pearana Prospect in Western Australia's Pilbara region, with assays peaking at 57% Mn and advancing towards drill-ready status.

Patronus Resources has initiated an on-market takeover offer for Matsa Resources at $0.045 per share, representing a significant premium and aiming to consolidate its position in gold exploration.

Euroz Hartleys, acting for Patronus Resources, has launched an unconditional on-market takeover bid for Matsa Resources at A$0.045 per share, aiming to acquire all shares not already controlled. The offer period runs from February 24 to March 24, 2025.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

Coolabah Metals Limited is undertaking a $3-4 million capital raise to fund the acquisition of Broken Hill Mines Pty Ltd and its subsidiary, aiming to re-list on the ASX and focus on developing the Rasp and Pinnacles Mines.